FDA Class III Recall: Cipla USA's Nilotinib Capsules Fail Stability Specifications, Impacting U.S. Supply
Cipla USA Inc. has initiated a voluntary Class III recall (D-0382-2026) for 164 cartons of Nilotinib Capsules, 200 mg, distributed nationwide. This action stems from out-of-specification results for description and visual appearance observed during 6-month long-term stability testing for Lot 5GJ0223. Procurement and regulatory teams must assess supply chain continuity for this critical oncology drug and scrutinize quality oversight for contract manufacturers.
FDA Class III Recall: Cipla USA's Nilotinib Capsules Fail Stability Specifications
Cipla USA Inc. has initiated a voluntary Class III recall, designated D-0382-2026, for specific lots of its Nilotinib Capsules, 200 mg. This action, reported to the FDA on March 11, 2026, and initiated by the firm on February 18, 2026, targets 164 cartons of Lot #: 5GJ0223, with an expiration date of April 30, 2027. The primary reason for this recall is the failure of tablet/capsule specifications, specifically observed as out-of-specification (OOS) results during 6-month long-term stability testing. These OOS results pertained to the product's description test and its appearance by visual inspection. For procurement directors, this means an immediate disruption to the supply of this specific lot of Nilotinib Capsules. While a Class III classification indicates that the use of or exposure to the violative product is not likely to cause adverse health consequences, the underlying quality issue—stability failure—is a critical concern. Regulatory affairs heads must recognize that such failures highlight deficiencies in quality control and stability programs, necessitating a thorough review of their own internal processes and those of their partners. Supply chain VPs should assess the impact on inventory and distribution networks, particularly given the nationwide distribution pattern in the U.S. for this product (NDC 69097-032-74, 69097-032-56, 69097-032-17).
Quality Control Lapses Impact Cipla USA's Nilotinib Supply Chain Management
The recall of Nilotinib Capsules, 200 mg, by Cipla USA Inc., headquartered in Warren, NJ, highlights critical aspects of pharmaceutical supply chain management, particularly for products manufactured for a marketing authorization holder. The product description explicitly states "Manufactured for: Cipla USA, Inc., 10 Independence Boulevard, Suite 300, Warren, NJ 07059." This distinction means that while Cipla USA Inc. is the recalling firm and responsible for the product's market presence, the actual manufacturing may have occurred at a different facility, necessitating robust oversight of contract manufacturing organizations (CMOs). For business development executives, this event underscores the importance of comprehensive due diligence on manufacturing partners and the entire product lifecycle beyond initial market entry. Procurement directors must scrutinize their supplier qualification processes to ensure that CMOs adhere to the highest quality standards, especially concerning stability testing and visual inspection protocols. Regulatory affairs heads should review their agreements with contract manufacturers to ensure clear accountability for quality deviations and prompt corrective and preventive actions (CAPA). The affected product, identified by application number NDA218922, is a human prescription drug, emphasizing the stringent regulatory expectations for its quality and consistency.
Navigating Supply Chain Risk for Nilotinib in the U.S. Market
The nationwide distribution of the recalled Nilotinib Capsules, 200 mg, across the U.S. means that pharmacies, hospitals, and distributors throughout the country are directly affected by this Class III recall. The quantity of 164 cartons, while not massive, represents a disruption for specific healthcare providers and patients relying on Lot #: 5GJ0223. Nilotinib, classified as a Bcr-Abl Tyrosine Kinase Inhibitor, is a critical oncology drug, and any supply interruption, even for a Class III recall, demands immediate attention. Supply chain VPs must activate their risk mitigation strategies, focusing on identifying unaffected lots or alternative sources to ensure continuity of care for patients. This incident serves as a crucial reminder for procurement directors to diversify their sourcing strategies for essential medicines, reducing reliance on single suppliers or specific manufacturing lots. Regulatory affairs heads should monitor the FDA's updates on the recall's progress and Cipla USA Inc.'s remediation efforts, as these will influence future market availability and regulatory standing. The event highlights that even voluntary, firm-initiated recalls for quality issues can create significant logistical and reputational challenges across the pharmaceutical value chain.
Strategic Sourcing for Bcr-Abl Tyrosine Kinase Inhibitors: Identifying Alternative Nilotinib Suppliers
Given the recall of Cipla USA Inc.'s Nilotinib Capsules, procurement teams must proactively identify and qualify alternative suppliers for this critical Bcr-Abl Tyrosine Kinase Inhibitor. While the provided knowledge graph does not list specific alternative manufacturers for Nilotinib, the market for generic oncology drugs is dynamic. Business development executives should explore potential partnerships with other pharmaceutical companies that hold FDA approvals for generic Nilotinib or similar kinase inhibitors, ensuring a diversified supply base. For procurement directors, this involves initiating or accelerating supplier qualification processes, which typically include comprehensive audits of manufacturing facilities, quality management systems, and regulatory compliance history. Geographic diversity in sourcing is paramount to mitigate risks associated with regional regulatory actions or supply chain vulnerabilities. Regulatory affairs heads must ensure that any new supplier's product meets all necessary FDA requirements, including bioequivalence and stability data, to facilitate a smooth transition. The objective is to secure a resilient supply chain for Nilotinib, minimizing future disruptions and safeguarding patient access to essential cancer treatments.
Broader Regulatory Environment: Contextualizing Cipla USA's Recall Within Industry Scrutiny
While the provided knowledge graph does not detail specific prior regulatory actions for Cipla USA Inc., this recall occurs within a broader landscape of heightened FDA scrutiny across the pharmaceutical industry. Recent parallel events underscore the agency's focus on fundamental quality attributes. For instance, Essential Wellness Pharma and Spectra Medical Devices faced Class II recalls due to sterility assurance deficiencies in progesterone and lidocaine injections, respectively. Guardian Drug Co. Inc. initiated a nationwide recall for metallic contamination in calcium carbonate antacids, and Eugia US LLC recalled Lidocaine HCl Injection for labeling deficiencies. For regulatory affairs heads, these concurrent events signal that the FDA maintains a vigilant stance on manufacturing quality, product specifications, and labeling integrity. This environment means that even Class III recalls, like Cipla USA's Nilotinib issue, are scrutinized as part of a company's overall compliance profile. Business development executives considering partnerships or acquisitions must factor in the target company's entire regulatory history, not just major enforcement actions. The collective trend indicates that all players in the chemical and life sciences industry must continuously invest in robust quality management systems to avoid regulatory actions and maintain market access.
Cipla USA's Path Forward: Remediation and Market Reassurance for Nilotinib Supply
The ongoing status of Cipla USA Inc.'s voluntary recall for Nilotinib Capsules signifies that the company is actively engaged in addressing the identified quality issues. The immediate next steps for Cipla USA Inc. will involve a thorough root cause analysis to determine why the Nilotinib capsules failed description and visual inspection tests at the 6-month long-term stability condition. Following this, the company must implement comprehensive corrective and preventive actions (CAPA) to prevent recurrence, which will likely include adjustments to manufacturing processes, quality control procedures, or stability testing protocols. For procurement directors, closely monitoring Cipla USA Inc.'s remediation progress is crucial for assessing the future reliability of their Nilotinib supply. Regulatory affairs heads must ensure that Cipla USA Inc.'s CAPA plan is robust and effectively addresses the FDA's expectations, potentially involving re-submission of stability data or manufacturing process changes. Supply chain VPs should maintain open communication channels with Cipla USA Inc. to understand the timeline for resolution and the availability of compliant product. This incident underscores the necessity for supplier agreements to clearly define responsibilities for quality deviations and the expected remediation timelines, ensuring minimal long-term impact on patient access to essential medicines like Nilotinib.